secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2022-06-17T23:59:59+00:00
Accession:  0001737287-22-000039
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene shareholders elect directors, approve authorized share increase to 400M
--------------------------------------------------------------------------------

- Four Class I directors elected: Elizabeth Barrett, Arie Belldegrun, David Bonderman, David Chang.
- Advisory vote on executive compensation passed: 103,325,400 for, 7,596,094 against.
- Authorized common shares increased from 200M to 400M; amendment filed June 16, 2022.
- Stock option exchange program approved: 77,394,629 for, 33,536,201 against.
- Ernst & Young ratified as auditor for FY2022: 125,514,754 for, 49,928 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728722000039/0001737287-22-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728722000039/allo-20220615.htm
  HTML page:      https://secwatch.observer/filing/0001737287-22-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer